Shortened duration of viral shedding in the nelfinavir treated patients
throat
EVALUABLE
For the primary endpoint of time to clinical recovery (TTCR), which was the time to convert to negative throat swab of SARS-CoV-2, the nelfinavir group had a 5.5 day shorter median time (9.0 days [IQR 5.0–11.0]) than the control group (14.5 days [6.0–25.0], Outcomes over time. Clinical improvement was observed in the nelfinavir group with a shorter TTCR time of 7.0 days (1.0~ NE (Not Evaluable), As of the 7th and 14th days of treatment, the proportion of subjects whose respiratory specimens were negative for SARS-CoV-2 RNA was 31.6% and 68.4% in the nelfinavir group (